These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30310468)

  • 21. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
    Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a Soluble Guanylate Cyclase Stimulator Riociguat on Contractility of Isolated Pulmonary Artery and Hemodynamics of U46619-Induced Pulmonary Hypertension in Dogs.
    Kameshima S; Nakamura Y; Uehara K; Kodama T; Yamawaki H; Nishi K; Okano S; Niijima R; Kimura Y; Itoh N
    Vet Sci; 2023 Feb; 10(2):. PubMed ID: 36851463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical treatment update on pulmonary arterial hypertension.
    Enderby CY; Burger C
    Ther Adv Chronic Dis; 2015 Sep; 6(5):264-72. PubMed ID: 26336595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
    Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
    J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
    Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
    Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
    Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
    Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
    Potoka KP; Wood KC; Baust JJ; Bueno M; Hahn SA; Vanderpool RR; Bachman T; Mallampalli GM; Osei-Hwedieh DO; Schrott V; Sun B; Bullock GC; Becker-Pelster EM; Wittwer M; Stampfuss J; Mathar I; Stasch JP; Truebel H; Sandner P; Mora AL; Straub AC; Gladwin MT
    Am J Respir Cell Mol Biol; 2018 May; 58(5):636-647. PubMed ID: 29268036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapies in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
    Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
    Kuroda K; Akagi S; Nakamura K; Sarashina T; Ejiri K; Ito H
    Heart Lung Circ; 2020 Mar; 29(3):331-336. PubMed ID: 30773322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
    Loukanov T; Geiger R; Agrawal R
    Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Riociguat for the treatment of pulmonary hypertension.
    Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
    Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.
    Raina A; Benza RL; Farber HW
    Pulm Circ; 2017; 7(3):741-746. PubMed ID: 28671485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pulmonary arterial hypertension (PAH ) : a new era of pulmonary arterial vasodilatators].
    Guiot J; Cornia O; Louis R
    Rev Med Liege; 2020 May; 75(5-6):344-349. PubMed ID: 32496677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.
    Benza R; Mathai S; Nathan SD
    Respir Med; 2017 Jan; 122 Suppl 1():S28-S34. PubMed ID: 27890470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
    Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
    Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulating NO-GC Pathway in Pulmonary Arterial Hypertension.
    D'Agostino A; Lanzafame LG; Buono L; Crisci G; D'Assante R; Leone I; De Vito L; Bossone E; Cittadini A; Marra AM
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erectile Dysfunction in Heme-Deficient Nitric Oxide-Unresponsive Soluble Guanylate Cyclase Knock-In Mice.
    Decaluwé K; Pauwels B; Boydens C; Thoonen R; Buys ES; Brouckaert P; Van de Voorde J
    J Sex Med; 2017 Feb; 14(2):196-204. PubMed ID: 28161078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.